CN104334542A - 作为磷酸二酯酶抑制剂的1-苯基-2-吡啶基烷基醇的衍生物 - Google Patents

作为磷酸二酯酶抑制剂的1-苯基-2-吡啶基烷基醇的衍生物 Download PDF

Info

Publication number
CN104334542A
CN104334542A CN201380029435.2A CN201380029435A CN104334542A CN 104334542 A CN104334542 A CN 104334542A CN 201380029435 A CN201380029435 A CN 201380029435A CN 104334542 A CN104334542 A CN 104334542A
Authority
CN
China
Prior art keywords
phenyl
methoxy
ethyl
pyridine
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380029435.2A
Other languages
English (en)
Chinese (zh)
Inventor
E·阿玛尼
C·卡帕蒂
L·卡尔萨尼加
O·埃斯珀西多
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chiesi Farmaceutici SpA
Original Assignee
Chiesi Farmaceutici SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiesi Farmaceutici SpA filed Critical Chiesi Farmaceutici SpA
Publication of CN104334542A publication Critical patent/CN104334542A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
CN201380029435.2A 2012-06-04 2013-05-28 作为磷酸二酯酶抑制剂的1-苯基-2-吡啶基烷基醇的衍生物 Pending CN104334542A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12170714 2012-06-04
EP12170714.5 2012-06-04
PCT/EP2013/060915 WO2013182451A1 (en) 2012-06-04 2013-05-28 Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors

Publications (1)

Publication Number Publication Date
CN104334542A true CN104334542A (zh) 2015-02-04

Family

ID=48670496

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380029435.2A Pending CN104334542A (zh) 2012-06-04 2013-05-28 作为磷酸二酯酶抑制剂的1-苯基-2-吡啶基烷基醇的衍生物

Country Status (11)

Country Link
US (1) US9440954B2 (cg-RX-API-DMAC10.html)
EP (1) EP2855450B1 (cg-RX-API-DMAC10.html)
KR (1) KR20150022789A (cg-RX-API-DMAC10.html)
CN (1) CN104334542A (cg-RX-API-DMAC10.html)
AR (1) AR091261A1 (cg-RX-API-DMAC10.html)
BR (1) BR112014029642A2 (cg-RX-API-DMAC10.html)
CA (1) CA2875421A1 (cg-RX-API-DMAC10.html)
HK (1) HK1205116A1 (cg-RX-API-DMAC10.html)
IN (1) IN2014DN10239A (cg-RX-API-DMAC10.html)
RU (1) RU2637945C2 (cg-RX-API-DMAC10.html)
WO (1) WO2013182451A1 (cg-RX-API-DMAC10.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116082670A (zh) * 2023-04-11 2023-05-09 中国人民解放军军事科学院军事医学研究院 一种含有季膦盐的声响应假性共轭聚合物纳米颗粒的制备方法及其在抗菌领域的应用

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2022783A1 (en) 2007-08-08 2009-02-11 CHIESI FARMACEUTICI S.p.A. "Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors"
EP2216327A1 (en) 2009-02-06 2010-08-11 CHIESI FARMACEUTICI S.p.A. Benzoic acid (1-phenyl-2-pyridin-4-yl)ethyl esters as phosphodiesterase inhibitors
PH12013502516A1 (en) 2011-06-06 2017-08-23 Chiesi Farm Spa Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
CN103827088B (zh) 2011-09-26 2017-10-13 奇斯药制品公司 作为磷酸二酯酶抑制剂的1‑苯基‑2‑吡啶基烷基醇的衍生物
CA2893628C (en) 2012-12-05 2021-11-30 Chiesi Farmaceutici S.P.A. 1-phenyl-2-pyridinyl alkyl alcohol derivatives as phosphodiesterase inhibitors
CA2893622A1 (en) 2012-12-05 2014-06-12 Chiesi Farmaceutici S.P.A. Novel compounds
TR201807181T4 (tr) 2012-12-05 2018-06-21 Chiesi Farm Spa Pde-4 i̇nhi̇bi̇törleri̇ ve muskari̇ni̇k reseptör antagoni̇stleri̇ olarak feni̇leti̇lpi̇ri̇di̇n türevleri̇
CN104837828B (zh) 2012-12-05 2017-07-18 奇斯药制品公司 作为pde4‑抑制剂的苯基乙基吡啶衍生物
AR104822A1 (es) * 2015-06-01 2017-08-16 Chiesi Farm Spa Derivado de aminoésteres
TW201710254A (zh) * 2015-06-01 2017-03-16 吉斯藥品公司 胺基酯衍生物
JP7575952B2 (ja) 2019-01-08 2024-10-30 杏林製薬株式会社 １５－ｐｇｄｈ阻害薬
WO2020160151A1 (en) 2019-01-31 2020-08-06 Kyorin Pharmaceutical Co., Ltd. 15-pgdh inhibitors

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101796028A (zh) * 2007-08-08 2010-08-04 奇斯药制品公司 1-苯基-2-吡啶基烷醇的衍生物作为磷酸二酯酶抑制剂

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL106517A0 (en) 1992-07-28 1994-08-26 Rhone Poulenc Rorer Ltd Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic or heteroatom containing linking group
US5786354A (en) 1994-06-21 1998-07-28 Celltech Therapeutics, Limited Tri-substituted phenyl derivatives and processes for their preparation
WO2004096274A1 (ja) 2003-03-31 2004-11-11 Kyowa Hakko Kogyo Co., Ltd. 気道内投与剤
DE602007012105D1 (de) * 2006-07-14 2011-03-03 Chiesi Farma Spa Derivate von 1-phenyl-2-pyridinylalkylenalkohole als phosphodiesteraseinhibitoren
PL2114951T3 (pl) * 2007-02-28 2014-10-31 Leo Pharma As Nowe inhibitory fosfodiesterazy
EP2070913A1 (en) 2007-12-14 2009-06-17 CHIESI FARMACEUTICI S.p.A. Ester derivatives as phosphodiesterase inhibitors
EP2110375A1 (en) 2008-04-14 2009-10-21 CHIESI FARMACEUTICI S.p.A. Phosphodiesterase-4 inhibitors belonging to the tertiary amine class
EP2216327A1 (en) 2009-02-06 2010-08-11 CHIESI FARMACEUTICI S.p.A. Benzoic acid (1-phenyl-2-pyridin-4-yl)ethyl esters as phosphodiesterase inhibitors
PH12013502516A1 (en) 2011-06-06 2017-08-23 Chiesi Farm Spa Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
CN103827088B (zh) 2011-09-26 2017-10-13 奇斯药制品公司 作为磷酸二酯酶抑制剂的1‑苯基‑2‑吡啶基烷基醇的衍生物
KR20140078719A (ko) 2011-10-21 2014-06-25 키에시 파르마슈티시 엣스. 피. 에이. 포스포디에스테라제 억제제로서 1-페닐-2-피리디닐 알킬 알코올의 유도체

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101796028A (zh) * 2007-08-08 2010-08-04 奇斯药制品公司 1-苯基-2-吡啶基烷醇的衍生物作为磷酸二酯酶抑制剂

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116082670A (zh) * 2023-04-11 2023-05-09 中国人民解放军军事科学院军事医学研究院 一种含有季膦盐的声响应假性共轭聚合物纳米颗粒的制备方法及其在抗菌领域的应用
CN116082670B (zh) * 2023-04-11 2023-06-27 中国人民解放军军事科学院军事医学研究院 一种含有季膦盐的声响应假性共轭聚合物纳米颗粒的制备方法及其在抗菌领域的应用

Also Published As

Publication number Publication date
WO2013182451A1 (en) 2013-12-12
RU2014148316A (ru) 2016-07-27
WO2013182451A9 (en) 2014-02-06
KR20150022789A (ko) 2015-03-04
EP2855450A1 (en) 2015-04-08
US20130324501A1 (en) 2013-12-05
IN2014DN10239A (cg-RX-API-DMAC10.html) 2015-08-07
BR112014029642A2 (pt) 2017-06-27
CA2875421A1 (en) 2013-12-12
EP2855450B1 (en) 2016-07-06
US9440954B2 (en) 2016-09-13
AR091261A1 (es) 2015-01-21
RU2637945C2 (ru) 2017-12-08
HK1205116A1 (en) 2015-12-11

Similar Documents

Publication Publication Date Title
RU2637945C2 (ru) Производные 1-фенил-2-пиридинил-алкиловых спиртов в качестве ингибиторов фосфодиэстеразы
CN103827088B (zh) 作为磷酸二酯酶抑制剂的1‑苯基‑2‑吡啶基烷基醇的衍生物
CN106946848B (zh) 作为磷酸二酯酶抑制剂的1-苯基-2-吡啶基烷基醇的衍生物
KR100747401B1 (ko) 프로스타글란딘 ｅ2 길항제로서의 페닐 또는 피리딜 아미드 화합물
CN102317262B (zh) 苯甲酸(1-苯基-2-吡啶基-4-基)乙酯作为磷酸二酯酶抑制剂
CN102791690B (zh) 作为抗癌药的二取代吡啶衍生物
IL322853A (en) History of 1-(([1,1'-biphenyl]-2-yl)sulfonyl)-4-fluoro-n-(3-(methylsulfonyl)allyl)piperidine-4-carboxamide as ras-pi3k modulators for exemplary cancer therapy
TW201827426A (zh) 具有ｇｌｐ－１受體促效作用的吡唑并吡啶衍生物
TW200304808A (en) N,N'-substituted-1,3-diamino-2-hydroxypropane derivatives
TWI891227B (zh) 用於治療與apj受體活性相關的病狀的化合物及組成物
WO2009077068A9 (en) Ester derivatives as phosphodiesterase inhibitors
CN111566103A (zh) 作为激酶抑制剂的氨基咪唑并吡嗪
CN103889972A (zh) 作为磷酸二酯酶抑制剂的1-苯基-2-吡啶基烷基醇的衍生物
TW201625601A (zh) 噻吩－２－基－吡啶－２－基－１ｈ－吡唑－４－羧酸衍生物及其作為可溶性鳥苷酸環化酶活化劑之用途
EA033679B1 (ru) Пиридинондикарбоксамиды для применения в качестве ингибиторов бромодомена
TWI628166B (zh) 作為磷酸二酯酶抑制劑之１－苯基－２－吡啶基烷基醇衍生物
JP2013047223A (ja) 医薬
CN103906734A (zh) 被取代的甲磺酰胺衍生物作为类香草素受体配体
KR20140085470A (ko) 바닐로이드 수용체 리간드로서의 아민 치환된 메탄설폰아미드 유도체
HK40089406A (en) Dihydrofuropyridine derivatives as rho- kinase inhibitors
HK40088595A (en) Dihydrofuropyridine derivatives as rho-kinase inhibitors
HK1235785A1 (en) Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
HK1235785B (en) Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
TW201102368A (en) Anticancer derivatives, preparation thereof and therapeutic use thereof
HK1194728A (en) Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1205116

Country of ref document: HK

RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20150204

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1205116

Country of ref document: HK